Fred Aslan, Chief Executive Officer at Artiva Biotherapeutics, Inc. (ARTV), sold 23,429 shares at $10.92 ($256K) on 2026-09-08, disclosed to the SEC on 2026-09-09.
Scheduled sale ($256k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ARTV | SELL | 2025-12-15 | $19K | — | Filing → |
| ARTV | SELL | 2025-11-17 | $22K | — | Filing → |
| ARTV | SELL | 2025-10-17 | $153K | — | Filing → |